secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2025-12-11T23:59:59+00:00
Accession:  0001193125-25-315074
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa appoints Mario Accardi as CEO; Saurabh Saha steps down effective Jan 1, 2026
--------------------------------------------------------------------------------

- Mario Accardi, President of Orexin Program, becomes CEO on Jan 1, 2026; Saha becomes advisor.
- Accardi's base salary set at $600k, target bonus 50%, equity awards target $6M.
- Company focuses on orexin franchise; ORX750 registrational program expected to start Q1 2026.
- Accardi founded Orexia (acquired by Centessa in 2021) and raised €40M Series A.
- Saha resignation not due to any disagreement with company's operations or policies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000119312525315074/0001193125-25-315074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000119312525315074/d933269d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-315074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer